Egyszerű nézet

dc.contributor.author Attarbaschi A
dc.contributor.author Beishuizen A
dc.contributor.author Mann G
dc.contributor.author Rosolen A
dc.contributor.author Mori T
dc.contributor.author Uyttebroeck A
dc.contributor.author Niggli F
dc.contributor.author Csóka, Monika
dc.contributor.author Krenova Z
dc.contributor.author Mellgren K
dc.contributor.author Kabickova E
dc.contributor.author Chiang AK
dc.contributor.author Reiter A
dc.contributor.author Williams D
dc.contributor.author Burkhardt B
dc.date.accessioned 2016-10-05T11:46:09Z
dc.date.available 2016-10-05T11:46:09Z
dc.date.issued 2013
dc.identifier 84885603589
dc.identifier.citation pagination=1537-1541; journalVolume=92; journalIssueNumber=11; journalTitle=ANNALS OF HEMATOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2375
dc.identifier.uri doi:10.1007/s00277-013-1785-2
dc.description.abstract Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL and/or i-BFM study group members was to assess clinical characteristics and course in a series of 63 pFL patients. pFL was found to be associated with male gender (3:1), older age (72 % ≥10 years old), low serum LDH levels (<500 U/l in 75 %), grade 3 histology (in 88 %), and limited disease (87 % stage I/II disease), mostly involving the peripheral lymph nodes. Forty-four out of sixty-three patients received any polychemotherapy and 1/63 rituximab only, while 17/63 underwent a "watch and wait" strategy. Of 36 stage I patients, 30 had complete resections. Only one patient relapsed; 2-year event-free survival and overall survival were 94 ± 5 and 100 %, respectively, after a median follow-up of 2.2 years. Conclusively, treatment outcome in pFL seems to be excellent with risk-adapted chemotherapy or after complete resection and an observational strategy only. © 2013 Springer-Verlag Berlin Heidelberg.
dc.relation.ispartof urn:issn:0939-5555
dc.title Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection
dc.type Journal Article
dc.date.updated 2015-11-20T09:31:43Z
dc.language.rfc3066 en
dc.identifier.mtmt 2351115
dc.identifier.wos 000325357600012
dc.identifier.pubmed 23665980
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet